/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel accommodating IOL achieves unique level of accommodative change


    Advance to primates

    The next step in the development of the AD-IOL will be to confirm the results observed in bench studies in eyes of living primates. The AD-IOL procedure involves two stages. First, the lens is implanted in the bag by applying the same technique as for a standard monofocal IOL.

    Dual-mode AD-IOL sized for a primate eye, next to a dime. The IOL is similar in size and thickness to a standard monofocal IOL. (Image courtesy of Paul Beer, MD)

    “The IOL is the same size as a regular IOL,” Dr. Beer said. “It is locked in a flattened, disaccommodated configuration.”

    After allowing four to six weeks for the capsule to collapse, fibrose, and adhere to the haptics, the IOL is unlocked. Radial capsulotomies are created in a non-invasive procedure using a laser (Nd:YAG or femtosecond), releasing optic mobility.

    Research conducted with the first version of the accommodating IOL, designed to achieve axial shift with accommodation/disaccommodation, proved that the zonular capture haptics could convert zonular force into optic movement. However, as expected, the axial-shifting AD-IOL exhibited a limited range of accommodation.

    “Zonular-capture haptics is an enabling technology that can be used in different ways,” Dr. Beer explained. “The dual-mode AD-IOL is designed to achieve both axial shift and an optic shape change with a system that can work in a closed and fibrosed capsular bag to achieve at least 15 D of accommodative change in the eye at the same force level as the previous model.”


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results